R&D productivity continues to be the industry's grand challenge. We analyzed the R&D
input, output, and outcome of 16 leading research-based pharmaceutical companies over …

Abstract The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for
some medicines with high Medicare spending. Using historical data from public and …

Rare disease (RD) patients face significant unmet therapeutic needs worldwide. However,
orphan drugs approved in the United States, but not approved or developed in Japan, have …

Economists' standard notion of intellectual property rights considers a single patent per
product, with a clearly defined scope, certain enforcement, and a fixed term of monopoly …

Highlights•The selection and focus on regions and therapeutic areas.•Large companies
achieved higher performance due to their regional focus.•Small/mid-sized companies …

Often described as a natural economic trend, the prices that pharmaceutical companies
charge for new medicines have skyrocketed in recent years. Companies claim these prices …

In clinical drug development, two fundamental questions remain unanswered: what is the
success rate of drugs in clinical trial? how does such rate change over time? Herein, a …

We analyze the relationship between firms' ability to leverage regulatory slack and their
market entry strategies. Using newly constructed genomic measures of disease market …

Continuous manufacturing (CM) of pharmaceutical products has gained a great deal of
interest over the past decade. CM promises multiple benefits to all pharmaceutical industry …

We analyze firms' market entry decisions in the presence of entry regulation. Our empirical
context is pharmaceuticals, where we show that firms prioritize larger markets for clinical …